BridgeMD
New treatment option for Frontotemporal Lobar Degeneration (FTLD)
Official title Single-centre Descriptive Study of Taste in Frontotemporal Lobar Degeneration Through the Analysis of Taste Evoked Potentials
ClinicalTrials.gov ID: NCT07110207
What this study is testing
What is Blood test?
Blood test is an investigational medicine, being studied as a potential treatment for frontotemporal lobar degeneration (ftld).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The FRONTAL-PEG study focuses on taste perception in frontotemporal lobar degeneration (FTLD). This neurodegenerative disease, characterised by progressive loss of nerve cells, is the second leading cause of dementia after Alzheimer's disease.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Person who has given their free and informed consent
- Person of legal age
- Fasting \> 2 hours before PEG measurement
- Body Mass Index (BMI) \< 30 kg/m² (according to medical record data)
- DLFT: diagnostic criteria for established or probable DLFT
You likely can't join if
- Persons not affiliated with or not covered by a social security scheme
- Persons subject to legal protection measures (guardianship, trusteeship)
- Persons subject to judicial protection measures
- Pregnant women, women in labour or breastfeeding women
- MMSE score \< 15 and/or MoCA score \< 10
- Known COVID-19 infection within 6 months prior to inclusion
See the full eligibility criteria
- Person who has given their free and informed consent
- Person of legal age
- Fasting \> 2 hours before PEG measurement
- Body Mass Index (BMI) \< 30 kg/m² (according to medical record data)
- DLFT: diagnostic criteria for established or probable DLFT
- Persons not affiliated with or not covered by a social security scheme
- Persons subject to legal protection measures (guardianship, trusteeship)
- Persons subject to judicial protection measures
- Pregnant women, women in labour or breastfeeding women
- MMSE score \< 15 and/or MoCA score \< 10
- Known COVID-19 infection within 6 months prior to inclusion
- Active smokers (\> 4 cigarettes per day on a regular basis)
- Subject with a pacemaker (contraindication for bioelectrical impedance analysis)
- Subject with diabetes (type 1 or type 2)
- Taking medication (during the study) that interferes with taste
The study team makes the final eligibility decision.
Where it's taking place
- Dijon, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dijon, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.